1. Home
  2. APLT vs MFIC Comparison

APLT vs MFIC Comparison

Compare APLT & MFIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLT
  • MFIC
  • Stock Information
  • Founded
  • APLT 2016
  • MFIC 2004
  • Country
  • APLT United States
  • MFIC United States
  • Employees
  • APLT N/A
  • MFIC N/A
  • Industry
  • APLT Biotechnology: Pharmaceutical Preparations
  • MFIC Finance/Investors Services
  • Sector
  • APLT Health Care
  • MFIC Finance
  • Exchange
  • APLT Nasdaq
  • MFIC Nasdaq
  • Market Cap
  • APLT 52.9M
  • MFIC 1.1B
  • IPO Year
  • APLT 2019
  • MFIC 2004
  • Fundamental
  • Price
  • APLT $0.33
  • MFIC $12.71
  • Analyst Decision
  • APLT Buy
  • MFIC Buy
  • Analyst Count
  • APLT 7
  • MFIC 5
  • Target Price
  • APLT $6.10
  • MFIC $13.60
  • AVG Volume (30 Days)
  • APLT 2.3M
  • MFIC 456.0K
  • Earning Date
  • APLT 08-06-2025
  • MFIC 08-06-2025
  • Dividend Yield
  • APLT N/A
  • MFIC 11.96%
  • EPS Growth
  • APLT N/A
  • MFIC N/A
  • EPS
  • APLT N/A
  • MFIC 1.22
  • Revenue
  • APLT $265,000.00
  • MFIC $312,149,000.00
  • Revenue This Year
  • APLT $1,768.13
  • MFIC $9.71
  • Revenue Next Year
  • APLT $292.85
  • MFIC $0.21
  • P/E Ratio
  • APLT N/A
  • MFIC $10.43
  • Revenue Growth
  • APLT N/A
  • MFIC 12.66
  • 52 Week Low
  • APLT $0.30
  • MFIC $10.18
  • 52 Week High
  • APLT $10.62
  • MFIC $15.70
  • Technical
  • Relative Strength Index (RSI)
  • APLT 43.25
  • MFIC 56.06
  • Support Level
  • APLT $0.30
  • MFIC $12.44
  • Resistance Level
  • APLT $0.36
  • MFIC $12.67
  • Average True Range (ATR)
  • APLT 0.03
  • MFIC 0.20
  • MACD
  • APLT -0.00
  • MFIC 0.02
  • Stochastic Oscillator
  • APLT 22.22
  • MFIC 87.84

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

About MFIC MidCap Financial Investment Corporation

MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.

Share on Social Networks: